An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS and microarray technologies are among the most trusted in the world. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants—and potentially transform the cancer care cycle.
We’re committed to advancing and individualizing the way cancer will be identified and treated. We want to partner with you in helping propel progress in personalized oncology. Together we can work toward achieving our ultimate goal: to make discoveries that will make a life-changing difference to cancer patients and their loved ones.
In this talk, Swetha Anandhan from the MD Anderson Cancer Center will highlight the use of single cell RNA-sequencing to identify a unique population of macrophages in glioblastoma multiforme that persists after treatment with immune checkpoint inhibitors.View Webinar